Parameter
| Biomarker | cfDNA | Full name | Cell-free DNA | Molecular Type | Nucleic acids (fragments of DNA) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | ~150-200 bp (~99-132 kDa) | Core Functional Dimensions | Monitoring of myocardial damage and assessment of graft rejection | |
| Disease | Heart failure | Disease Subtypes | / | ||
| Organ | Heart failure | Test Sample / Technology Platform | Plasma (real-time qPCR, Shotgun sequencing) | ||
| Pathobiological Mechanisms | Myocardial cells are released during apoptosis/necrosis to reflect the degree of myocardial injury. Donor-derived cfDNA (cfdDNA) can monitor rejection after heart transplantation | ||||
| Clinical Availability Status | Study validation/specific scenarios available: - GRAfT queue confirmed cfdDNA monitoring acute heart transplant rejection of AUC = 0.92; -cfDNA >10ng/ml in acute HF suggests a 2.3-fold increase in 30-day mortality | ||||
| Notes and Dynamics | Heart transplantation in cfdDNA > 0.25% can be diagnosed acute rejection (sensitivity 81%, specificity 85%), 81% less invasive biopsy; Acute HF cfDNA level and cardiac troponin I (cTnI) positive correlation (r = 0.51), and reflect the degree of myocardial injury; The black HF patients after transplantation cfdDNA rise 2 times that of white patients, need to pay close attention to racial differences | ||||